Gundesen MT, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Madsen JS, Asmussen JT, Teodorescu EM, Jensen BA, Slørdahl TS, Nielsen AA, Olsen DA, Søe K, Nahi H, Waage A, Abildgaard N, Schjesvold F, Lund T (2026)
Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers
Br J Haematol (in press)
DOI 10.1111/bjh.70612, PubMed 42581608

van de Donk NWCJ, Schjesvold F, van der Holt B, Minnema MC, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Bringhen S, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro M, Gay F, Sonneveld P, Musto P (2026)
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients
Blood Cancer J, 16 (1)
DOI 10.1038/s41408-026-01549-0, PubMed 42337226

Ludwig H, Terpos E, Gay F, van de Donk NWCJ, Bernhard S, Engelhardt M, Cook G, Schjesvold F, Einsele H, Jackson G, Pawlyn C, Mateos MV, Zweegman S, Schreder M, Beksaç M, Driessen C, Ocio EM, Popat R, Rasche L, Touzeau C, Musto P, Broijl A, Dimopoulos M, Hajek R, Boccadoro M, Sonneveld P (2026)
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)
Am J Hematol, 101 (9), 2353-2370
DOI 10.1002/ajh.70397, PubMed 42315477